FOS‐Mediated PLCB1 Induces Radioresistance and Weakens the Antitumor Effects of CD8 + T Cells in Triple‐Negative Breast Cancer
Molecular Carcinogenesis · 2025
DOI: 10.1002/mc.23834 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2025. Verfasst von Yuxian Shu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Comprehensive Radiotherapy, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People's Republic of China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Radiation Tolerance, Phospholipase C beta, CD8-Positive T-Lymphocytes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
Radioresistance and immune evasion are interactive and crucial events leading to treatment failure and progression of human malignancies. This research studies the role of phospholipase C beta 1 (PLCB1) in these events in triple‐negative breast cancer (TNBC) and the regulatory mechanism. PLCB1 was bioinformatically predicted as a dysregulated gene potentially linked to radioresistance in TNBC. Parental TNBC cell lines were exposed to fractionated radiation for 6 weeks. PLCB1 expression was decreased in the first 2 weeks but gradually increased from Week 3. PLCB1 knockdown increased the radiosensitivity of the cells, as manifested by a decreased half‐inhibitory dose of irradiation, reduced cell proliferation, apoptosis resistance, mobility, and tumorigenesis in mice. The FOS transcription factor promoted PLCB1 transcription and activated the PI3K/AKT signaling. Knockdown of FOS similarly reduced radioresistance and T cells‐mediated immune evasion. However, the radiosensitivity of TNBC cells and the antitumor effects of CD8 + T cells could be affected by a PI3K/AKT activator or by the PLCB1 upregulation. The PLCB1 or FOS knockdown also suppressed radioresistance and tumorigenesis of the TNBC cells in mice. In conclusion, FOS‐mediated PLCB1 induces radioresistance and weakens the antitumor effects of CD8 + T cells in TNBC by activating the PI3K/AKT signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Comprehensive Radiotherapy, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People's Republic of China.
- First Department of General Surgery, Jiangxi Gao'an People's Hospital, Gao'an, Jiangxi, People's Republic of China.
- Department of Oncology, Taihe County People's Hospital, Ji'an, Jiangxi, People's Republic of China.
- Department of Oncology, No.908 Hospital, Joint Logistics Support Force, Nanchang, Jiangxi, People's Republic of China.
- Department of Oncology, Taihe County Traditional Chinese Medicine Hospital, Ji'an, Jiangxi, People's Republic of China.
- Department of Breast Surgery, Jiangxi Cancer Hospital, Nanchang, Jiangxi, People's Republic of China.
Zitieren
APA
Shu, Y., Lan, J., Luo, H., Fu, H., Xiao, X., & Yang, L. (2025). FOS‐Mediated PLCB1 Induces Radioresistance and Weakens the Antitumor Effects of CD8 + T Cells in Triple‐Negative Breast Cancer. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23834
Vancouver
Shu Y, Lan J, Luo H, Fu H, Xiao X, Yang L. FOS‐Mediated PLCB1 Induces Radioresistance and Weakens the Antitumor Effects of CD8 + T Cells in Triple‐Negative Breast Cancer. Molecular Carcinogenesis. 2025. doi:10.1002/mc.23834
BibTeX
@article{Shu2025,
author = {Shu, Yuxian and Lan, Jun and Luo, Huijing and Fu, Huiying and Xiao, Xuhuang and Yang, Liping},
title = {FOS‐Mediated PLCB1 Induces Radioresistance and Weakens the Antitumor Effects of CD8 + T Cells in Triple‐Negative Breast Cancer},
journal = {Molecular Carcinogenesis},
year = {2025},
doi = {10.1002/mc.23834}
}
EUVIMED